一种选择性一期活化部分凝血活酶时间凝血测定法和两种显色测定法用于非acog beta pegol给药后监测的资格确认
本研究在三个独立站点系统评估了STA-Cephascreen APTT试剂的一期凝血法、ROX Factor IX和BIOPHEN Factor IX显色法测定非acog beta pegol(N9-GP)回收率的准确度与精密度。结果显示三种方法在五种试剂-仪器系统上均表现可接受的性能,STA-Cephascreen在一个站点报告范围有限,BIOPHEN在一个站点低端灵敏度可疑,但可通过调整报告范围解决,不影响资格确认。结论认为这三种方法可用于3.2%(0.109 m)枸橼酸化人血浆中N9-GP的测定。
要点
- STA-Cephascreen一期凝血法、ROX Factor IX和BIOPHEN Factor IX显色法均被确认可用于测定N9-GP。
- 三种方法在五个试剂-仪器系统上显示可接受的批内和批间准确度与精密度。
- STA-Cephascreen在一个站点报告范围有限,BIOPHEN在一个站点低端灵敏度可疑。
核心结论
- STA-Cephascreen APTT试剂的一期凝血法、ROX Factor IX显色法和BIOPHEN Factor IX显色法被认为可用于3.2%(0.109 m)枸橼酸化人血浆中N9-GP的测定。
研究设计与样本
- 在三个独立站点,采用制造商推荐方案和/或站点特定测定设置(包括不同仪器),系统评估三种FIX活性测定法在加入N9-GP的血友病B血浆样本中的准确度和精密度。
主要发现
- 三种FIX活性测定法在五种不同试剂-仪器系统上均显示可接受的批内和批间准确度与精密度、稀释完整性、试剂稳健性以及冻融和短期样本稳定性。
- STA-Cephascreen测定法在三个资格确认站点之一显示报告范围有限。
- BIOPHEN Factor IX测定法在三个资格确认站点之一显示低端灵敏度可疑。
关键数值与推荐
- STA-Cephascreen APTT试剂的一期凝血法、ROX Factor IX显色法和BIOPHEN Factor IX显色法被认为可用于3.2%(0.109 m)枸橼酸化人血浆中N9-GP的测定。
局限性
- STA-Cephascreen测定法在三个资格确认站点之一显示报告范围有限,BIOPHEN Factor IX测定法在三个资格确认站点之一显示低端灵敏度可疑;个体实验室可通过调整测定的报告范围来应对这些限制,因此这些发现被认为不影响各自测定的资格确认。
- 其他半衰期延长的凝血因子产品应在获批前以类似方式进行评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Nonacog beta pegol (N9-GP) is an extended half-life, recombinant human factor IX (FIX). One-stage clotting (OSC) and chromogenic FIX activity assays were assessed for N9-GP recovery. OSC STA® -Cephascreen® , ROX FIX and BIOPHEN FIX chromogenic assays were qualified for N9-GP. Other extended half-life factor products should be assessed in a similar way prior to approval. SUMMARY: Background Nonacog beta pegol (N9-GP) is an extended half-life, glycoPEGylated recombinant human factor IX that is under development for the prophylaxis and treatment of bleeding episodes in hemophilia B patients. Considerable reagent-dependent variability has been observed when one-stage clotting assays are used to measure the recovery of recombinant FIX products, including N9-GP. Objective To qualify select one-stage clotting and chromogenic FIX activity assays for measuring N9-GP recovery. Methods The accuracy and precision of the one-stage clotting assay (with the STA-Cephascreen activated partial thromboplastin [APTT] reagent) and the ROX Factor IX and BIOPHEN Factor IX chromogenic assays for measuring N9-GP recovery were assessed in N9-GP-spiked hemophilia B plasma samples in a systematic manner at three independent sites, with manufacturer-recommended protocols and/or site-specific assay setups, including different instruments. Results For each of the three FIX activity assays qualified on five different reagent-instrument systems, acceptable intra-assay and interassay accuracy and precision, dilution integrity, reagent robustness and freeze-thaw and short-term sample stabilities were demonstrated. The STA-Cephascreen assay showed a limited reportable range at one of the three qualification sites, and the BIOPHEN Factor IX assay showed suspect low-end sensitivity at one of the three qualification sites. An individual laboratory would account for these limitations by adjusting the assay's reportable range; thus, these findings are not considered to impact the respective assay qualifications. Conclusion The one-stage clotting assay with the STA-Cephascreen APTT reagent, the ROX Factor IX chromogenic assay and the BIOPHEN Factor IX chromogenic assay are considered to be qualified for the measurement of N9-GP in 3.2% (0.109 m) citrated human plasma.
引用
- Tiefenbacher S, Bohra R, Amiral J, et al. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol. J Thromb Haemost. 2017. PMID: 28772338. doi:10.1111/jth.13787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。